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Abstract
Background: Molecular mechanisms regulating leuko-
cyte sequestration into the tissue during endotoxemia
and/or sepsis are still poorly understood. This in vivo
study investigates the biological role of murine PECAM-1
and VCAM-1 for leukocyte sequestration into the lung,
liver and striated skin muscle. Methods: Male BALB/c
mice were injected intravenously with murine PECAM-1
IgG chimera or monoclonal antibody (mAb) to VCAM-1
(3 mg/kg body weight); controls received equivalent
doses of IgG2a (n = 6 per group). Fifteen minutes thereaf-
ter, 2 mg/kg body weight of Salmonella abortus equi
endotoxin was injected intravenously. At 24 h after the
endotoxin challenge, lungs, livers and striated muscle of
skin were analyzed for their myeloperoxidase activity. To
monitor intravital leukocyte-endothelial cell interactions,
fluorescence videomicroscopy was performed in the
skin fold chamber model of the BALB/c mouse at 3, 8 and
24 h after injection of endotoxin. Results: Myeloperoxi-
dase activity at 24 h after the endotoxin challenge in
lungs (12,171 B 2,357 mU/g tissue), livers (2,204 B
238 mU/g) and striated muscle of the skin (1,161 B
110 mU/g) was significantly reduced in both treatment
groups as compared to controls, with strongest attenua-
tion in the PECAM-1 IgG treatment group. Arteriolar leu-
kocyte sticking at 3 h after endotoxin (230 B 46 cells !
mm–2) was significantly reduced in both treatment
groups. Leukocyte sticking in postcapillary venules at 8 h
after endotoxin (343 B 69 cells/mm2) was found reduced
only in the VCAM-1-mAb-treated animals (215 B 53
cells/mm2), while it was enhanced in animals treated
with PECAM-1 IgG (572 B 126 cells/mm2). Conclusion:
These data show that both PECAM-1 and VCAM-1 are
involved in endotoxin-induced leukocyte sequestration
in the lung, liver and muscle, presumably through inter-
ference with arteriolar and/or venular leukocyte sticking.
Copyright © 2004 S. Karger AG, Basel
Introduction
The characteristic findings during endotoxemia are
fever, initial leukopenia which may later on lead to
peripheral leukocytosis and thrombocytopenia. Cyto-
kines, especially interleukin (IL) 1ß, tumor necrosis factor
(TNF) · and Á-interferon, are the key mediators for prop-
agation of this systemic inflammatory reaction which is
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accompanied by a systemic leukocyte activation state [1,
2]. Activation of leukocytes and endothelial cells results in
aggregation of leukocytes, platelets and erythrocytes in
vivo. This may favor disseminated intravasal coagulation
and may result in multiple organ failure [3]. Therapeutic
strategies aiming at the blockade of the involved inflam-
matory mediators such as TNF-· or IL-1 have shown to
improve the outcome under various experimental settings
[4–6], while this holds not true under clinical conditions
[7].
Adhesion molecules both on leukocytes and endothe-
lial cells can be stimulated by lipopolysaccharides or cyto-
kines such as TNF-· or IL-1. Among those adhesion mole-
cules, platelet-endothelial cell adhesion molecule 1 (PE-
CAM-1, CD31) and vascular cell adhesion molecule 1
(VCAM-1, CD106) have been suggested to play a vital
role for leukocyte transmigration and emigration into the
perivascular tissue [8–10]. PECAM-1 is constitutively
expressed on endothelial cells, platelets and several leuko-
cyte subpopulations [11]. Therefore it can undergo multi-
ple cellular interactions through homophilic and/or hete-
rophilic binding. Moreover, it has been shown that PE-
CAM-1 plays a role in cell signaling as has been described
for its supportive function on the activation state of leuko-
cyte integrins [12], the affinity state of the VCAM-1/
VLA-4 adhesion system [13] and as a signaling, adaptor
and adhesion molecule [14]. VCAM-1 is known to play a
pathophysiological role in organ transplantation and ath-
erosclerosis [15, 16]. The expression of VCAM-1 during
endotoxemia is mediated through the release of IL-1 and
TNF-· at 3 and 6 h after stimulation, respectively [8]. The
biological effects of this adhesion molecule may therefore
be expected at the earliest about 5–8 h after injection of
endotoxin.
The aim of this study was to investigate the role of
PECAM-1 and VCAM-1 during severe endotoxemia on
(i) leukocyte sequestration into the lung, liver and striated
muscle of skin and (ii) microvascular leukocyte-endothe-
lial cell interaction in arterioles and postcapillary venules
of striated muscle of skin.
Material and Methods
Antibodies
The following antibodies against murine antigens were used:
PECAM-1 IgG was prepared as described by Liao et al. [12]. This
chimeric PECAM-1 construct has been shown to competitively block
PECAM-1 both in vitro and in vivo with a long-lasting in vivo half-
life of more than 24 h and without activating the complement cas-
cade or interfering with the peripheral leukocyte count in vivo [17].
Rat IgG2a served as control antibody (Dianova, Hamburg, Germa-
ny). Aliquots of the injectable solutions were tested for endotoxin
with the limulus amebocyte test (Boehringer, Mannheim, Germany).
The maximal endotoxin dose an animal received by injection of the
solution was !0.75 ng.
Monoclonal antibodies (mAbs) to VCAM-1 were obtained from
Prof. Dr. D. Vestweber (Institute for Immunobiology, University of
Münster, Germany). Anti-VCAM-1 mAb was a IgG2a rat antibody,
clone AK2-C5. This antibody was purified and concentrated by col-
umn chromatography (Prof. Dr. G. Enders, Institute for Surgical
Research, University of Munich, Germany). The specificity of this
antibody has been tested earlier [18].
Endotoxin
Endotoxin of Salmonella abortus equi was obtained from Prof. C.
Galanos (Max Planck Institute for Immunobiology, Freiburg, Ger-
many) and administered intravenously at a dose of 2 mg/kg body
weight. Endotoxin was regularly aliquoted before the experiment and
assessed with the limulus amebocyte test before injection.
Myeloperoxidase
Myeloperoxidase (MPO) activity was assessed in the tissues of the
animals at the end of the observation period of 24 h. For this pur-
pose, lungs, livers and the striated skin muscle tissues were excised
under ketamine hydrochloride (125 mg/kg body weight, Ketavet®,
Parke Davis, Freiburg, Germany) and xylazine (15 mg/kg, Rom-
pun®, Bayer, Leverkusen, Germany) anesthesia. The measurement
of enzyme activity was performed according to the technique by
Kuebler et al. [19].
Animal Model
Intravital fluorescence microscopy was used for investigation of
leukocyte-endothelial cell interactions in the dorsal skin fold cham-
ber model of the striated muscle of skin of BALB/c mice. The surgical
technique has been described previously [20]. All experiments have
been approved by the Local Ethical Committee of the Government
of Bavaria (AZ: 211-2531-4693).
Intravital Fluorescence Microscopy
A 25-fold water immersion objective (total magnification: 560-
fold; E. Leitz Inc., Wetzlar, Germany) was used to select 4–6 sites of
interest per chamber, each containing one or several postcapillary
venules (between 10–40 Ìm and 40–80 Ìm in diameter) and arteri-
oles (10–60 Ìm in diameter). By means of a computer-controlled
stepping-motor-driven platform [21], the identical vessel segments
were investigated with respect to leukocyte/endothelium interaction,
vessel diameter and red blood cell velocity before administration of
the antibody solutions and at 3, 8 and 24 h after injection of S. abor-
tus equi endotoxin (2 mg/kg body weight). For visualization of leuko-
cytes, the in vivo fluorescent marker rhodamine 6G (Sigma Chemical
Co., Deisenhofen, Germany) was infused intravenously as a bolus of
0.15 mg/kg body weight 10 min before the intravital microscopic
recordings. Epi-illumination was achieved with an HBO mercury
lamp attached to a Ploemopak illuminator with an N2 filter block
(Leitz). For visualization of the plasma, the I2/3 filter block (Leitz)
was used after bolus infusion of the in vivo fluorescent plasma mark-
er fluorescein isothiocyanate (FITC)-dextran (Pharmacia, Uppsala,
Sweden; molecular weight 150 kDa; 15 mg/kg body weight i.v.). This
double fluorescence technique allowed for sequential investigation of
vessel diameter and red blood cell velocity on the one hand, and
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Fig. 1. MPO activity in lung (a), liver (b) and striated muscle of skin
(c) of BALB/c mice taken at 24 h after injection of 2 mg/kg body
weight S. abortus equi endotoxin. Control animals received 3 mg/kg
body weight of an isotype-matched antibody (rat IgG2a, n = 7). Ani-
mals of the treatment groups received equivalent doses of PECAM-1
IgG or anti-VCAM-1 mAb (each n = 6). Note the different scaling of
the vertical axis: MPO activity in the lung was approximately 10-fold
that of the striated muscle of skin tissue, whereas MPO activity in the
liver was approximately 2-fold that of the striated skin muscle tissue.
Mean B SEM, a p ! 0.05 versus IgG2a, b p ! 0.05 versus anti-
VCAM-1 mAb, Kruskal-Wallis test.
leukocyte/endothelium interaction on the other hand in the identical
vessel segment [20, 22]. The microscopic images (Camera COHU
4400; Prospective Measurements, San Diego, Calif., USA) were
recorded on videotape for 30 s using both filter blocks consecutively,
providing enough time for analysis of the video images by playback
employing a computer-assisted microcirculation analysis system
[21]. Red blood cell velocity was assessed offline by a cross-correla-
tion technique using the Capiflow system (Capiflow version 3.1;
Lawrence Co., Sulzbach, Germany).
Microcirculatory Parameters
According to their interaction with the microvascular endothe-
lium, sticking leukocytes were defined as cells that do not move or
detach from the endothelial lining within an observation time of 30 s
and are expressed as cells per square millimeter of endothelial sur-
face, calculated from diameter and length (200 Ìm) of the vessel seg-
ment under investigation. The microhemodynamic parameters ves-
sel diameter and red blood cell velocity were assessed in each vessel
segment.
Experimental Protocol
For quantification of the effects of the antibodies on leukocyte
sticking during endotoxemia, PECAM-1 IgG and mAb against
VCAM-1 were administered 15 min prior to infusion of endotoxin as
intravenous bolus injection of 3 mg/kg body weight, respectively.
Intravital microscopic measurements were made before antibody
administration and at 3, 8 and 24 h after injection of endotoxin. Ani-
mals were randomly assigned to control and treatment groups. Con-
trol animals received equivalent doses of an isotype-matched control
antibody (rat IgG2a, n = 7). Treatment animals received 3 mg/kg
body weight of either PECAM-1 IgG (n = 6) or anti-VCAM-1 mAb
(n = 6).
Statistical Analysis
Paired data of more than two samples were analyzed using Fried-
man’s nonparametric test for two-way analysis of variance and com-
parison on ranks for multiple samples. For unpaired data of multiple
samples the Kruskal-Wallis test was used with Bonferroni correction
of p (Unistat® Statistical Package Version 1.2, 1984–1993, Unistat
Ltd., UK). p values !0.05 were considered significant. Despite non-
parametric data distribution, data are given in text and figures as
arithmetic means B SEM to facilitate interpretation of data pub-
lished in the literature.
Results
Effects of PECAM-1 IgG and Anti-VCAM-1 mAb on
Endotoxin-Induced Leukocyte Sequestration into
Lung, Liver and Striated Muscle of Skin in BALB/c
Mice
MPO activity was assessed in lungs, livers and striated
skin muscle tissues of BALB/c mice both under base-
line conditions and 24 h after endotoxin administration.
Under baseline conditions, there was a trend for en-
hanced MPO activity to be observed in the lung (479 B
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Fig. 2. Leukocyte sticking in arterioles of the
striated muscle of skin in BALB/c mice be-
fore and at the given time points after injec-
tion of 2 mg/kg body weight S. abortus equi
endotoxin. Control animals received equiva-
lent doses of an isotype-matched control an-
tibody (rat IgG2a, n = 7). Animals of the
treatment groups received equivalent doses
of 3 mg/kg body weight PECAM-1 IgG or
anti-VCAM-1 mAb (n = 6). Mean B SEM,
a p ! 0.05 versus baseline, Friedman test;
b p ! 0.05 versus IgG2a, c p ! 0.05 versus
PECAM-1 IgG, Kruskal-Wallis test.
250 mU/g tissue) and liver (281 B 72 mU/g tissue) when
compared to the striated skin muscle (193 B 98 mU/g
tissue). At 24 h of endotoxemia, MPO activity was dra-
matically increased in all tissues of IgG2a-treated con-
trol animals (n = 7) compared to animals treated with
PECAM-1 IgG or anti-VCAM-1 mAb (fig. 1a–c). There
was a tendency for PECAM-1 IgG to be more effective
than anti-VCAM-1 mAb treatment in the prevention of
leukocyte sequestration into all tissues, which reached sig-
nificance only in striated skin muscle.
Effects of PECAM-1 IgG and Anti-VCAM-1 mAb on
Endotoxin-Induced Leukocyte Sticking in Arterioles
and Postcapillary Venules of Murine Striated Muscle
of Skin
Leukocyte sticking was observed both in arterioles and
postcapillary venules after injection of endotoxin. In arte-
rioles, a significant increase in leukocyte sticking was
found with a maximum at 3 h after endotoxin (fig. 2).
This increase was effectively reduced by PECAM-1 IgG as
compared to IgG2a-treated control animals and was fur-
ther attenuated by mAb to VCAM-1. In animals treated
with anti-VCAM-1 mAb, the reduction of arteriolar stick-
ing was significantly more effective at 3 h after endotoxin
as compared with PECAM-1-treated animals. At 24 h
after endotoxin there were no more significant differences
of leukocyte sticking to be detected.
In postcapillary venules of the striated muscle of skin,
leukocyte sticking under baseline conditions ranged be-
tween 20 and 40 cells/mm2 endothelial surface (fig. 3). A
significant increase in venular leukocyte sticking was
observed in IgG2a-treated animals after the endotoxin
challenge. The response in postcapillary venules of ani-
mals treated with PECAM-1 IgG or VCAM-1 mAb was
different from that observed in arterioles. There was no
attenuation, but in contrast an enhancement of leukocyte
sticking in animals receiving the PECAM-1 IgG chimera
at 8 h after endotoxin, while a reduction of leukocyte
sticking by about 40% was seen at 8 h after endotoxin in
animals treated with mAb to VCAM-1.
Discussion
In this study, we demonstrate that the sequestration of
leukocytes into the lung, liver and striated skin muscle of
BALB/c mice is effectively attenuated by blockade of ei-
ther PECAM-1 or VCAM-1. Leukocyte adhesive inter-
actions were monitored at 3, 8 and 24 h after injection
of endotoxin. We found that both adhesion molecules,
PECAM-1 and VCAM-1, are involved in arteriolar leuko-
cyte sticking in the striated skin muscle, while in postcap-
illary venules no inhibitory effects were observed after
blockade of PECAM-1 and only temporary effects were
seen after blockade of VCAM-1 at 8 h after the endotoxin
challenge. In control animals, there was a massive (25-
fold) increase in MPO activity in the lungs, followed by an
8-fold increase in the liver and a 6-fold one in striated skin
PECAM-1 and VCAM-1 in Murine
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Fig. 3. Leukocyte sticking in postcapillary
venules of the striated muscle of skin in
BALB/c mice before and at the given time
points after injection of 2 mg/kg body weight
S. abortus equi endotoxin. Control animals
received 3 mg/kg body weight of an isotype-
matched control antibody (rat IgG2a, n = 7).
Animals of the treatment groups received
equivalent doses of 3 mg/kg body weight
PECAM-1 IgG or anti-VCAM-1 mAb (n =
6). Mean B SEM, a p ! 0.05 versus baseline,
Friedman test; b p ! 0.05 versus IgG2a, c p !
0.05 versus PECAM-1 IgG, Kruskal-Wallis
test.
muscle tissue (fig. 1a–c) as compared to baseline values
assessed in normal BALB/c mice. Both blockade of
VCAM-1 and PECAM-1 resulted in a significant reduc-
tion of leukocyte accumulation in these organs whereby
blockade of PECAM-1 seemed to be more effective.
Our findings using mAb to VCAM-1 to reduce pulmo-
nary injury (fig. 1a) are supported by other studies dem-
onstrating in remote organ injury models of obstructive
cholangitis or mesenteric ischemia-reperfusion an upreg-
ulation of this adhesion molecule associated with pulmo-
nary sequestration [23, 24]. Upregulation of VCAM-1 in
response to TNF-· has been reported in the lung, liver and
kidneys [25, 26]. Callicutt et al. [27] have shown in a pan-
creatitis-induced lung injury model in mice that thera-
peutic blockade of VCAM-1 reduces pulmonary leuko-
cyte sequestration and, in consequence, lung injury.
However, there are only few data on the role of
PECAM-1 in endotoxin-induced pulmonary injury. Va-
porciyan et al. [9] have shown in three different (nonendo-
toxin) in vivo models of inflammation that PECAM-1 is
involved in neutrophil transmigration into the alveolar
compartment of the lung. There is both in vitro and in
vivo evidence for expression of PECAM-1 in the pulmo-
nary vascular bed as assessed in oxidative stress models
[28]. Moreover, it has been reported that catalase conju-
gated to PECAM-1 mAb rapidly accumulates in the lungs
after intravenous injection into mice and protects from
pulmonary injury in a murine lung model of oxidative
stress [29]. Hence, our findings provide first in vivo evi-
dence for the functional role of PECAM-1 in pulmonary
leukocyte sequestration during endotoxemia in mice
(fig. 1a).
Both adhesion molecules have been shown to play sig-
nificant roles in leukocyte-mediated hepatocellular tissue
damage. This finding is supported by our MPO data dem-
onstrating a significant reduction of leukocyte accumu-
lation in the liver in response to endotoxemia (fig. 1b).
Expression of VCAM-1 in rat liver cells is strongly
enhanced upon injection of endotoxin [30]. Essani et al.
[31] have demonstrated that neutrophils use the VLA-4/
VCAM-1 adhesion system for transmigration into the liv-
er parenchyma in vivo. The selective blockade by anti-
VCAM-1 mAb protected from hepatocellular injury in
endotoxic shock [31].
Chosay et al. [32] have shown in a previous study that
endotoxin alone or in combination with galactosamine
elicits neutrophil margination in liver sinusoids and post-
sinusoidal venules while emigration occurred only after
administration of the combination of endotoxin with
galactosamine at the site of the sinusoids. Our finding of
an enhanced leukocyte accumulation upon injection of
endotoxin alone may be attributed to the significantly
higher dose of endotoxin used in this study. At the dose of
2 mg/kg body weight S. abortus equi used in our study, as
compared to 100 Ìg/kg body weight used by Chosay et al.
[32], additional trigger mechanisms for leukocyte trans-
migration may be activated, perhaps in a dose-dependent
fashion. Moreover, the authors demonstrated in an im-
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munohistological investigation that PECAM-1 is ex-
pressed in postsinusoidal veins of the liver, but not in sinu-
soidal venules [33], making them conclude that PECAM-1
does not play a functional role for leukocyte sequestration
in the liver. This finding is contrary to our results showing
that blockade of PECAM-1 was associated with a signifi-
cant reduction of MPO activity (fig. 1b). In a recent study
by Neubauer et al. [34] however, constitutional expression
of PECAM-1 has been reported both in rat and human
livers as well as isolated rat sinusoidal endothelial cells,
hepatic stellate cells and hepatocytes. The discrepancy
between these studies may in part be due either to species-
or endotoxin-dependent (Escherichia coli vs. S. abortus
equi) differences. It may furthermore be speculated that in
the absence of PECAM-1 expression in sinusoidal endo-
thelial cells as observed by Chosay et al. [33], platelet depo-
sition may taper the endothelial lining of the sinusoids,
thus allowing platelet-derived PECAM-1 to support leuko-
cyte transmigration through the sinusoidal endothelium.
Nevertheless, our study clearly supports the functional role
of PECAM-1 for leukocyte sequestration into the livers of
BALB/c mice during severe endotoxemia.
In the present study, we moreover demonstrate a role
for both VCAM-1 and PECAM-1 in endotoxin-induced
leukocyte sticking and sequestration into the striated
muscle of the skin as assessed by the MPO activity at 24 h
after endotoxin (fig. 1c). These findings have to be inter-
preted in view of the intravital videomicroscopic observa-
tions: a significant increase in arteriolar leukocyte sticking
was observed with a maximum at 3 h after injection of
endotoxin (fig. 2) as has previously been described by our
group [35]. Other investigators have also reported on arte-
riolar leukocyte rolling and sticking upon injection of
E. coli endotoxin into hamsters [36]. Since injection of
TNF-· can also elicit arteriolar rolling in vivo [37], the
release of this cytokine in response to endotoxin may
account for this observation. We herein for the first
time demonstrate that blockade of either PECAM-1 or
VCAM-1 effectively reduces arteriolar leukocyte sticking,
indicating that both molecules are involved in this scenar-
io. This finding is not surprising in view of the role of
VCAM-1 which has been shown to play a crucial role in
atherogenesis [16].
At the venular side of the microcirculatory bed, leuko-
cyte sticking increased significantly after endotoxin, but
was attenuated by mAb to VCAM-1 at 8 h after endotoxin
(fig. 3). This finding coincides with the upregulation of
this adhesion molecule in response to endotoxin [30].
Interestingly, there was no reduction of endotoxin-in-
duced leukocyte sticking visible in animals treated with
PECAM-1 IgG. On the contrary, a significant increase in
leukocyte sticking at this time point of investigation in
animals treated with PECAM-1 IgG was observed. Simi-
lar findings have been reported by other investigators sug-
gesting that PECAM-1 may facilitate endothelial tighten-
ing by the intravascularly trapped leukocytes prevented
from transmigration [10]. Indeed, in a previous study
from our laboratory we have demonstrated macromolecu-
lar leakage of FITC-dextran 150 kDa from postcapillary
venules to be significantly attenuated in animals treated
with PECAM-1 IgG [38]. Therefore, increased leukocyte
sticking in postcapillary venules may not necessarily be
equated with increased endothelial cell injury. In conclu-
sion, both PECAM-1 and VCAM-1 are involved in leuko-
cyte adhesion and transmigration in postcapillary venules
of the striated skin muscle, however with different em-
phasis on the step involved in the adhesion cascade.
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